Moderna lifts annual revenue forecast | The Manila Times

Moderna raised its 2026 revenue forecast to 15-25% growth, up from 10%, due to strong vaccine demand and partnerships. Q3 revenue was $1.3B, beating estimates. The company reported a $162M profit, reversing last year's $200M loss. Shares rose over 10% after the announcement, driven by positive cancer vaccine data and future growth prospects.

Moderna (MRNA) shares rose 5.3% on November 6, 2026, after reporting Q3 revenue of $1.3B, beating estimates, and raising its 2026 revenue growth outlook to 15-25%. The company also reduced its R&D budget by $200M. The stock has gained 978.9% over the past year, with significant volatility.

GSK and Moderna settled their patent dispute over COVID-19 and RSV vaccine technology without payments. The agreement allows both to use each other's patented technologies. GSK sued Moderna in 2024, alleging patent infringement. The settlement covers Moderna's Spikevax, mNEXSPIKE, and mResvia vaccines. Both companies requested dismissal of GSK's US claims. This resolves one of several legal battles among pharmaceutical companies over COVID-19 vaccine technology.

Health Canada approved two Moderna mRNA vaccines: one for flu and another for flu and COVID-19. Approval is for individuals aged 50 and older. Moderna develops vaccines.

Moderna raised its yearly revenue forecast due to strong international demand for its COVID-19 vaccine and collaboration revenue, reporting a profitable third quarter. Its stock rose over 10%. The company's stock has increased over 800% this year, driven by positive late-stage trial results for its personalized cancer vaccine with Merck. Analyst Cory Kasimov of Evercore ISI called the results encouraging.

Moderna (MRNA) reported Q3 2026 revenue up 29% YoY, but costs rose 54%. The norovirus vaccine program was delayed. A $900M litigation charge impacted GAAP expenses. The company raised 2026 guidance, citing strong COVID vaccine performance and partnerships. Key trials and FDA discussions are ongoing.